FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000674705> ?p ?o ?g. }

• W2000674705 endingPage "1028" @default.
• W2000674705 startingPage "1023" @default.
• W2000674705 abstract "Background: Treatment of hepatitis C virus (HCV) has become a major challenge in HIV-infected individuals. No data exist on the efficacy and tolerability of pegylated IFN (peg-IFN) plus ribavirin in HIV-co-infected patients. Methods: Subcutaneous peg-IFN (150 μg weekly during the first 12 weeks and 100 μg weekly thereafter) plus ribavirin (400 mg twice a day) was given to 68 HIV-infected patients with chronic hepatitis C, having CD4 cell counts greater than 300 cells/μl, plasma HIV-RNA less than 5000 copies/ml, and elevated aminotransferase levels. All were naive for IFN, and 73% were receiving antiretroviral drugs. Results: Plasma HCV-RNA levels greater than 800 000 IU/ml were seen in 50%, and 35% carried HCV genotype 3. Adverse events leading to treatment discontinuation occurred in 10 patients (15%). One patient taking didanosine developed pancreatitis. Severe weight loss occurred in 70% of patients. Clearance of HCV-RNA at the end of therapy (6 months for HCV-3 and 12 months for HCV-1/4) occurred in 50% of patients (81% with HCV-3 versus 30% with HCV-1/4). As 30% relapsed, the overall sustained response rate was 35% (28% in the intent-to-treat analysis). The main predictors of response were infection with HCV-3 and low HCV load. Conclusion: Treatment with peg-IFN and ribavirin is relatively well-tolerated in HIV/HCV-co-infected patients, although new side-effects, including pancreatitis and severe weight loss, may result from the interaction of ribavirin with antiretroviral drugs. Overall, therapy provides cure to one third of patients, a rate significantly lower than that seen in HCV-monoinfected individuals. Given that relapses are common, extended periods of therapy should be investigated." @default.
• W2000674705 created "2016-06-24" @default.
• W2000674705 creator A5003553956 @default.
• W2000674705 creator A5005378862 @default.
• W2000674705 creator A5009751300 @default.
• W2000674705 creator A5017751675 @default.
• W2000674705 creator A5024021097 @default.
• W2000674705 creator A5027520171 @default.
• W2000674705 creator A5038424951 @default.
• W2000674705 creator A5048089201 @default.
• W2000674705 creator A5056870679 @default.
• W2000674705 creator A5058958091 @default.
• W2000674705 creator A5075118902 @default.
• W2000674705 creator A5084131412 @default.
• W2000674705 date "2003-05-01" @default.
• W2000674705 modified "2023-10-07" @default.
• W2000674705 title "Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients" @default.
• W2000674705 cites W1987268569 @default.
• W2000674705 cites W1993974155 @default.
• W2000674705 cites W2004602615 @default.
• W2000674705 cites W2016336666 @default.
• W2000674705 cites W2027545702 @default.
• W2000674705 cites W2027961253 @default.
• W2000674705 cites W2036313720 @default.
• W2000674705 cites W2052509705 @default.
• W2000674705 cites W2059268470 @default.
• W2000674705 cites W2079634214 @default.
• W2000674705 cites W2118047427 @default.
• W2000674705 cites W2122494591 @default.
• W2000674705 cites W2127685726 @default.
• W2000674705 cites W2165715544 @default.
• W2000674705 cites W2169882906 @default.
• W2000674705 cites W2317554121 @default.
• W2000674705 cites W2332630894 @default.
• W2000674705 cites W2333452860 @default.
• W2000674705 cites W2466165747 @default.
• W2000674705 cites W4256582478 @default.
• W2000674705 doi "https://doi.org/10.1097/00002030-200305020-00011" @default.
• W2000674705 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12700452" @default.
• W2000674705 hasPublicationYear "2003" @default.
• W2000674705 type Work @default.
• W2000674705 sameAs 2000674705 @default.
• W2000674705 citedByCount "202" @default.
• W2000674705 countsByYear W20006747052012 @default.
• W2000674705 countsByYear W20006747052013 @default.
• W2000674705 countsByYear W20006747052014 @default.
• W2000674705 countsByYear W20006747052015 @default.
• W2000674705 countsByYear W20006747052016 @default.
• W2000674705 countsByYear W20006747052017 @default.
• W2000674705 countsByYear W20006747052018 @default.
• W2000674705 countsByYear W20006747052019 @default.
• W2000674705 countsByYear W20006747052020 @default.
• W2000674705 countsByYear W20006747052021 @default.
• W2000674705 countsByYear W20006747052022 @default.
• W2000674705 crossrefType "journal-article" @default.
• W2000674705 hasAuthorship W2000674705A5003553956 @default.
• W2000674705 hasAuthorship W2000674705A5005378862 @default.
• W2000674705 hasAuthorship W2000674705A5009751300 @default.
• W2000674705 hasAuthorship W2000674705A5017751675 @default.
• W2000674705 hasAuthorship W2000674705A5024021097 @default.
• W2000674705 hasAuthorship W2000674705A5027520171 @default.
• W2000674705 hasAuthorship W2000674705A5038424951 @default.
• W2000674705 hasAuthorship W2000674705A5048089201 @default.
• W2000674705 hasAuthorship W2000674705A5056870679 @default.
• W2000674705 hasAuthorship W2000674705A5058958091 @default.
• W2000674705 hasAuthorship W2000674705A5075118902 @default.
• W2000674705 hasAuthorship W2000674705A5084131412 @default.
• W2000674705 hasBestOaLocation W20006747051 @default.
• W2000674705 hasConcept C126322002 @default.
• W2000674705 hasConcept C142462285 @default.
• W2000674705 hasConcept C197934379 @default.
• W2000674705 hasConcept C203014093 @default.
• W2000674705 hasConcept C2522874641 @default.
• W2000674705 hasConcept C2775967933 @default.
• W2000674705 hasConcept C2776408679 @default.
• W2000674705 hasConcept C2776455275 @default.
• W2000674705 hasConcept C2776461080 @default.
• W2000674705 hasConcept C2777447569 @default.
• W2000674705 hasConcept C2778375690 @default.
• W2000674705 hasConcept C2778715236 @default.
• W2000674705 hasConcept C2780040827 @default.
• W2000674705 hasConcept C2993143319 @default.
• W2000674705 hasConcept C71924100 @default.
• W2000674705 hasConcept C90924648 @default.
• W2000674705 hasConceptScore W2000674705C126322002 @default.
• W2000674705 hasConceptScore W2000674705C142462285 @default.
• W2000674705 hasConceptScore W2000674705C197934379 @default.
• W2000674705 hasConceptScore W2000674705C203014093 @default.
• W2000674705 hasConceptScore W2000674705C2522874641 @default.
• W2000674705 hasConceptScore W2000674705C2775967933 @default.
• W2000674705 hasConceptScore W2000674705C2776408679 @default.
• W2000674705 hasConceptScore W2000674705C2776455275 @default.
• W2000674705 hasConceptScore W2000674705C2776461080 @default.
• W2000674705 hasConceptScore W2000674705C2777447569 @default.
• W2000674705 hasConceptScore W2000674705C2778375690 @default.
• W2000674705 hasConceptScore W2000674705C2778715236 @default.
• W2000674705 hasConceptScore W2000674705C2780040827 @default.
• W2000674705 hasConceptScore W2000674705C2993143319 @default.

• next